Eli Lilly fronts $2 billion for vaccine biotech deals as Infinimmune secures $75 million funding

Eli Lilly announced it has paid $2 billion up front as part of its ongoing strategy to acquire vaccine‑focused biotechnology companies, a portion of a larger deal that could total up to $3.8 billion.

Infinimmune, a biotech developing immune‑modulating therapies, completed a financing round that raised $75 million to advance its pipeline.

The briefing also noted activity at several other biotech firms, including Tenax Therapeutics, Aureka Biotechnologies, ATyr Pharma, Prana Therapies and Mereo BioPharma, though no specific details were provided.

These moves reflect continued investor interest in vaccine and immunotherapy platforms as the sector seeks to expand its pipeline and address emerging health challenges.